Wealth Awesome
TSX closed
Loading markets…
PARTNER SPOTLIGHT
CIBC Investor's Edge

Buy the stocks you believe in, for less

For a limited time, trade fractional shares commission-free.¹

  • ✓Own a piece of your favourite companies without buying an entire share
  • ✓Stocks and ETFs, from as little as $1
  • ✓In any account: TFSA, FHSA, RRSP and more

¹Online fractional trades in North American equities under one share, Sep 15, 2026 to Oct 31, 2027. One qualifying order per security, per side, per day. Conditions apply.

Stocks/TSX/EPRX

Eupraxia Pharmaceuticals Inc (EPRX : TSX)

$6.12CAD-2.74 (-30.93%)Close of 2026-11-19

Common Stock

Follow EPRX

EPRX

Eupraxia Pharmaceuticals Inc

Source:WealthAwesomeWealthAwesome
↓ $1.95 (-18.17%)
30 day period
$8.78$10.21$11.65Oct 8Oct 30Nov 19

Performance

1 Day

-0.90%

1 Week

-20.97%

1 Month

-18.10%

YTD

-16.06%

The Saturday TSX Wrap · free, every saturday morning. The week on the TSX, in five minutes.

Key Statistics

Market Cap

$710.35M

52W High

$13.08

52W Low

$7.85

P/E Ratio

-

50 Day MA

$10.75

200 Day MA

$10.07

Beta

1.33

Dividend Yield

-

WA Score

How EPRX stacks up against 931 Canadian stocks

out of 99

  • Value15

    Not profitable over the last 12 months.

  • Quality
  • Momentum36

    −16.1% this year, below its 200-day average, 18% of the way up its 52-week range.

  • Analysts
  • Insiders

Each factor is a percentile against Canadian common stocks worth $50M or more on the TSX and TSX Venture (90 = better than 90% of them). Built from exchange prices, company financials, analyst targets and SEDI insider filings. A data summary, not advice. How it works · Top-scoring stocks

Performance history

EPRX returns since 2023

Eupraxia Pharmaceuticals Inc has traded since Nov 2023 in our data, with 1 up year out of 2 full calendar years. Its deepest fall was −57.7% (Feb 2024 to Oct 2024).

1 year / yr

−0.1%

3 years / yr

+13.3%

5 years / yr

—

10 years / yr

—

Calendar-year returns

  • 2023*−12.7%
  • 2024−16.0%
  • 2025+128.8%
  • 2026*−14.9%

* Partial year (first year of data, or year to date).

$10,000 invested in EPRX

  • 1 year ago$9,989
  • 2023 (start of our data)$14,276
Best year
2025: +128.8%
Worst year
2024: −16.0%
All-time high in our data
$13 on Sep 30, 2026 · now −32.4%

Total-return basis using adjusted daily closes from the Toronto Stock Exchange and TSX Venture (dividends and splits folded in), Nov 2023 to Nov 2026. Past returns do not predict future ones.

Earnings

EPRX earnings history

Eupraxia Pharmaceuticals Inc beat the EPS estimate in 1 of its last 4 reported quarters.

-0.5000-0.25000.0000 24-1225-0325-0625-0925-1226-0326-0626-09 Estimate Actual (≥0) Actual (<0) Wealth Awesome
Quarter endingReportedEPSEstimateSurprise
Sep 30, 2026Nov 10, 2026−$0.33−$0.36+8.3%
Jun 30, 2026Aug 11, 2026−$0.32−$0.32+0.0%
Mar 31, 2026May 7, 2026−$0.32−$0.19−68.5%
Dec 31, 2025Mar 12, 2026−$0.50−$0.22−127.3%
Sep 30, 2025Nov 4, 2025−$0.27−$0.27+0.0%
Jun 30, 2025Aug 12, 2025−$0.36−$0.25−44.0%
Mar 31, 2025May 6, 2025−$0.29−$0.23−26.1%
Dec 31, 2024Mar 20, 2025−$0.28−$0.16−75.0%

EPS as reported vs consensus estimate. TSX earnings calendar →

Awesome Portfolio™

Looking past EPRX? Our 10 best Canadian stocks, in one list.

14.8% a year since 2017 against 9.7% for the S&P/TSX Composite (+5.0 points a year). Reviewed every month.

See the portfolio →

Technical Indicators

Price vs 50-Day SMA

↓Below 50 SMA

Price vs 200-Day SMA

↓Below 200 SMA

Recent Price History

DateOpenHighLowCloseAdj CloseVolume
11/19/2026$9.23$9.29$8.74$8.78$8.7875,975
11/18/2026$9.50$9.50$8.76$8.86$8.86162,602
11/17/2026$10.36$10.49$9.36$9.45$9.45183,636
11/16/2026$11.50$11.56$10.48$10.56$10.56106,985
11/13/2026$11.11$11.71$10.88$11.65$11.6582,172
11/12/2026$11.21$11.43$10.87$11.11$11.1170,309
11/11/2026$11.11$12.00$11.11$11.45$11.45161,467
11/10/2026$10.26$10.88$10.25$10.86$10.8694,922
11/9/2026$9.91$10.80$9.86$10.46$10.4696,631
11/6/2026$9.26$9.72$9.24$9.71$9.7165,563

Analyst Price Targets

Based on analyst covering EPRX · as of Nov 18, 2026

📈

Wall Street analysts forecast EPRX stock price to rise 184.9% over the next 12 months.

Consensus

Bullish

Based on avg. target vs last close (formal rating unavailable for Canadian listings)

Avg. Target

C$17.43

+184.9% Upside

Previously C$16.33 on Sep 28, 2026

Current Price

C$6.12

Last close

Compare analyst targets →

Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on EPRX's historical volatility

HistoricalForecast68%95%
C$2.56C$6.26C$9.96C$13.66C$17.37C$21.07TodayJul 14Sep 17Nov 19Jan 1Feb 14Mar 29

30-Day Vol

85.7%

Annualized

90-Day Vol

81.0%

Annualized

Trend (90d)

-50.0%

Annualized drift

90d Mean

C$7.34

Expected price

HorizonExpected68% Range (1σ)
30 trading daysC$8.27C$6.15 – C$11.12
60 trading daysC$7.79C$5.13 – C$11.84
90 trading daysC$7.34C$4.40 – C$12.26

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

About Eupraxia Pharmaceuticals Inc

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

Financials

Revenue (TTM)
$0
EBITDA
$-65.98M
Profit Margin
0.00%
ROE (TTM)
-56.44%
EPS (Diluted)
-1.49
Book Value
1.91

Classification

Sector
Health Care
Industry
Biotechnology
Group
Pharmaceuticals, Biotechnology & Life Sciences

Free newsletter

The Saturday TSX Wrap

Saturday morning

The week on the TSX, in five minutes

  • The biggest gainers and losers, and why they moved
  • Sector and momentum moves at a glance
  • The Canadian market stories you missed

Free. One email a week. Unsubscribe any time.

Common Questions About EPRX

Market movers

Recent TSX movers

Top 1-day gainers — updated from our Canadian movers feed.

All movers →
TickerNamePrice1D
GRCGold Springs Resource Corp$0.06+37.50%
MDNAMedicenna Therapeutics Corp$0.22+22.22%
DRXADF Group Inc.$20.78+20.88%
DNDDye & Durham Ltd$0.98+13.95%
TTelus Corp$15.50+13.72%
BUBurcon NutraScience Corporation$0.85+13.33%
DII-BDorel Industries Inc$1.35+8.87%
PYRPyroGenesis Canada Inc.$0.19+8.57%

Free with a Wealth Awesome account

Keep analysing EPRX, free

  • Every WA Score, ranking and table
  • Insider track records and SEDI filings
  • Earnings history and analyst targets for every stock

Email only, no password, no card. Already a member? Use the same button to sign in.